Rosalie supports clients focused on clinical development, FDA engagement and filing, and broader lifecycle management strategies for drugs, biologics and medical devices.
Before joining Avalere, Rosalie conducted oncology research on drug target validation and preclinical development of small molecules. Previously, she contributed to market research and therapeutic landscape reports during her internship at ATP Ventures Partners. She also competed in the Merck KGaA Innovation Cup, developing a proprietary cancer therapeutic pitch for pharmaceutical executives.
Rosalie holds a PhD in medicinal chemistry from Virginia Commonwealth University and a BS in chemistry from the University of Virginia.
Authored Content
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.
Manufacturers can accelerate innovation and improve rare and ultra-rare disease therapy access by leveraging new and established regulatory pathways.
The 2025 edition of the annual report provides insights into state statutes on point-of-service substitution of biosimilar products and is available
The ACNU final rule provides a new approval pathway for prescription drugs to also gain nonprescription marketing status.
Drug compounding regulation has evolved due to recent industry trends, emphasizing the need to understand its optimal role in healthcare delivery.
A second Trump administration and Republican Congress will mark a shift in healthcare policy priorities in 2025 on both legislative and regulatory fronts.
Recent FDA authorization of Florida’s Section 804 Importation Program has prompted increased focus on importation pathways.